WO2017078353A1 - Composition including stipitalide as active ingredient - Google Patents

Composition including stipitalide as active ingredient Download PDF

Info

Publication number
WO2017078353A1
WO2017078353A1 PCT/KR2016/012406 KR2016012406W WO2017078353A1 WO 2017078353 A1 WO2017078353 A1 WO 2017078353A1 KR 2016012406 W KR2016012406 W KR 2016012406W WO 2017078353 A1 WO2017078353 A1 WO 2017078353A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
active ingredient
composition
stipitalide
Prior art date
Application number
PCT/KR2016/012406
Other languages
French (fr)
Korean (ko)
Inventor
윤철식
정용철
이재성
Original Assignee
윤철식
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윤철식 filed Critical 윤철식
Publication of WO2017078353A1 publication Critical patent/WO2017078353A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention is a pharmaceutical composition for oral disease prevention or treatment comprising a stipitalid extracted from the insect-derived fungus represented by the formula (1) as an active ingredient and health functional food, preservative composition or whitening pharmaceutical composition for prevention or improvement and It is about a cosmetic composition.
  • Oral diseases such as dental caries, gingivitis, periodontitis, and bad breath are fundamentally caused by Streptococcus mutans, Porphyromonas gingivalis, Prevotella intermedia, and actinobacilli fluid. It is known to be caused mainly by oral pathogens of the Candida spp., Including pathogenic microorganisms such as Actinobacillus actinomycetemcomitans, Candida albicans and the like.
  • antiseptic is a drug that prevents the corruption of the substance. It is antiseptic to prevent decaying of flora and fauna by the action of microorganisms, and a preservative is a chemical agent added for preservation for the purpose of preservation. Decaying microorganisms include fungi, fungi, yeast and bacteria that are lower organisms.
  • Such preservatives are generally added to prevent the deterioration of foods, cosmetics or medicines and the like and to maintain their purity while using or preserving them. Therefore, it is essential that there is no harm to the human body, and the addition should not impair the quality.
  • Food preservatives also known as food preservatives, should prevent food from being oxidized when exposed to air or prevent microorganisms such as mold and bacteria from corrupting food.
  • chemical preservatives such as calcium propionate, sodium benzoate, sodium nitrite and sorbic acid have been used. Propionic acid prevents mold and is used in bread, cheese and chocolate.
  • Sodium benzoate when added to orange juice or grapefruit juice, prevents the growth of microorganisms.
  • Sodium nitrite prevents the growth of microorganisms in meat. Sorbic acid and its salts inhibit the growth of mold and yeast, especially in cheese.
  • the use of such chemical preservatives is harmful to both humans and livestock when the amount is exceeded, and their use is regulated by the law (Pharmaceutical Law and Food Sanitation Law).
  • Cosmetic preservatives allow cosmetics to be stored at room temperature for a long time. Since cosmetics have to be used for a long time after opening, preservatives are added to protect consumers to prevent them from being easily changed. Preservatives commonly used in cosmetics are methyl paraben, ethyl paraben, ethoxy paraben, propyl paraben, butyl paraben, quaternium-15, imidazolidinyl urea (Imidazolidinyl Urea) and the like. However, cosmetics are used directly on the human body for life, so even a small amount of preservatives can have a significant effect on the human body.
  • sodium salts of benzoic acid are added to eye drops, homemade medicines, and injections. Such chemical preservatives can cause fatal harm to humans when exceeded, and according to the law (pharmaceutical and food hygiene) And usage are strictly controlled.
  • natural preservatives extracted from natural organisms in consideration of human safety aspects. So far, natural preservatives that suppress microbial contamination and growth have been developed, such as hinokitiol, a cypress extract, megnonole, and DF-100, a grapefruit seed extract. It's only about%, which doesn't meet demand.
  • melanin pigment which is the most important factor in determining skin color, is typified by tyrosinase, an amino acid that is normally present in the human body, to be dopa (DOPA) by tyrosinase, an enzyme present in melanocytes.
  • DOPA dopa
  • tyrosinase an amino acid that is normally present in the human body
  • DOPA dopa
  • tyrosinase an enzyme present in melanocytes.
  • tyrosinase enzymes which tyrosinase is an initial biosynthesis process in which tyrosine is transferred to L-dopaquinone as a substrate. It then acts on the oxidation of dihydroxyindole.
  • tyrosinase activity inhibitor is an important part of the development of the whitening agent, and the known tyrosinase inhibitors are currently known as hydroquinone, 4-hydroxyanisole, and ascorbic acid. acid derivatives, kojic acid, azelaic acid, corticosteroids, corticosteroids, retinoids, arbutin, catechin, etc., but problems such as safety and economics There is a difficulty in using it.
  • an object of the present invention is to provide a composition comprising a compound having a therapeutic effect, an antiseptic effect or a skin whitening effect.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of oral diseases comprising the compound of formula 1 as an active ingredient.
  • the present invention provides a health functional food for preventing or improving oral disease, comprising the compound of Formula 1 as an active ingredient.
  • the present invention also provides a preservative composition comprising the compound of Formula 1 as an active ingredient.
  • the present invention also provides a pharmaceutical composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
  • the present invention also provides a cosmetic composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
  • the present invention is a pharmaceutical composition for the prevention or treatment of oral diseases, including steipitalide (5,8-dihydroxy-1 H -cyclohepta- [ c ] furan-1,6 ( 3H ) -dione) as an active ingredient and improvement
  • steipitalide (5,8-dihydroxy-1 H -cyclohepta- [ c ] furan-1,6 ( 3H ) -dione)
  • the stypittalide is low toxicity and excellent antimicrobial activity against various bacteria and useful as a preservative of various products related to oral cavity, food, cosmetics or medicines Can be used.
  • it has excellent inhibitory activity against melanin synthesis and can be usefully used as a whitening related product composition.
  • 3 to 5 is a result of confirming the growth inhibitory activity of the bacteria associated with oral disease of stipitalid
  • the inventors of the present invention while evaluating the activity of the material obtained by extracting the fungus derived from insects with ethyl acetate (ethyl acetate), isolating and purifying, the inhibitory activity and various melanin production inhibitory activity against various bacteria including caries It was confirmed to complete the present invention.
  • the material is stipitalide (5,8-dihydroxy-1 H -cyclohepta- [c] furan-1,6 ( 3H ) -dione) represented by the following formula (1), Holika (Holik) and Ku ( Kuhr) 's paper (Miroslav Holik and Ivo Kuhr, J. Chem . Soc., Chem . Commun . 1973. 65-66) for the first time reported a chemical structure, but there is no study on the effect of the biological activity of this substance. to be.
  • Stypitalide represented by the formula (1) is a streptococcus mutans ( Streptococcus mutans ) is a caries ATCC25175, Streptococcus sorbrinus ATCC27607 and Porphyromonas Gingivalis gingivalis ) ATCC33277, Fusobacterium causes bad breath nucleatum ) ATCC23726 , Klebsiella pneumoniae The growth of ATCC15380 was effectively suppressed.
  • the present invention provides a pharmaceutical composition for preventing or treating oral disease, comprising the compound of Formula 1 as an active ingredient.
  • the oral disease is any one selected from the group consisting of dental caries, periodontitis and bad breath, but is not limited thereto.
  • the compound of Formula 1 is characterized in that it was isolated and purified from culture medium of Cordyceps sp.
  • Cordyceps species which are insect-derived fungi, are prone to change in appearance, as are other fungi, and all of their mutants, fusions or genetic recombinants are included in the scope of the present invention.
  • the strain is cultured in a medium containing a nutrient source normally used by microorganisms.
  • Nutrients include glucose, fructose, sucrose, dextrin, etc. as carbon sources, and tryptone, corn steep liquor (CSL), etc. as nitrogen sources. use.
  • a culture method under aerobic conditions in particular immersion culture method is suitable, the culture is carried out in a temperature range of 26 °C to 30 °C.
  • the target compound may be purified through a process such as adsorption chromatography, ethyl acetate extraction, gel filtration chromatography, and high pressure liquid chromatography.
  • the present invention provides a health functional food for preventing or improving oral diseases comprising the compound of Formula 1 as an active ingredient.
  • stipitalid represented by the formula (1) Mannheimia haemolytica known as bacteria causing diseases in humans and animals ( Mannheimia haemolytica ) ATCC43270MH, Pasteurella multocida ATCC43137PM , Enterococcus faecalis ) ATCC29212, Salmonella choleraesuis , Salmonella sui , Salmonella typhimurium , Streptococcus agalactiae , Streptococcus d'Arcactus , Streptococcus dilacris Streptococcus dysgalactiae), Salmonella yen Tara itty display (Salmonella enteritidi), Tino evil pneumoniae as Bacillus Fleur (Actinobacillus pleuropneumoniae) ATCC27090, Histophilus somni Inhibition of the growth of ATCC700025 and Staphylococcus neumoniae ATCC496
  • the present invention provides a preservative composition comprising the compound of formula 1 as an active ingredient.
  • the compound of Chemical Formula 1 is stetitallide (stipitalide) is purified from the culture medium of the cordyceps sp. (Cordyceps sp.), An insect-derived fungus, can be used in food, cosmetics or pharmaceuticals.
  • the present invention provides a pharmaceutical composition for skin whitening comprising the compound of formula 1 as an active ingredient.
  • the compound of Chemical Formula 1 is isolated and purified from culture medium of Cordyceps sp., which is an insect-derived fungus, as stepititalide.
  • the present invention provides a cosmetic composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
  • compositions according to the invention may further comprise suitable carriers, excipients or diluents commonly used in the manufacture of pharmaceutical compositions.
  • Carriers, excipients or diluents usable in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
  • compositions according to the present invention may be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
  • sterile injectable solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient, for example, starch, calcium carbonate, sucrose ( sucrose, lactose, gelatin and the like can be mixed and prepared.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the amount of stipitalide which is an active ingredient of the pharmaceutical composition according to the present invention may vary depending on the age, sex, weight, and disease of the patient, but is 0.001 to 50 mg / kg, preferably 0.001 to 5 mg / kg once daily. To multiple administrations.
  • the dosage of stipitalide according to the present invention may be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
  • the pharmaceutical composition may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrabronchial inhalation, intrauterine dural or intracerebroventricular injection.
  • the health functional food according to the present invention may be provided in the form of powder, granules, tablets, capsules, syrups or beverages, and the health functional food is used together with other foods or food additives in addition to stipitalide as an active ingredient, and It can be suitably used according to the phosphorus method.
  • the mixed amount of the active ingredient can be suitably determined depending on the purpose of use thereof, for example, prophylactic, health or therapeutic treatment.
  • dietary supplements for example, meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea , A drink, an alcoholic beverage, and a vitamin complex.
  • the cosmetic composition according to the present invention may include conventional adjuvants such as stabilizers, solubilizers, vitamins, pigments and flavors, and a carrier, in addition to stipitalide which is an active ingredient.
  • adjuvants such as stabilizers, solubilizers, vitamins, pigments and flavors, and a carrier, in addition to stipitalide which is an active ingredient.
  • the cosmetic composition may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, cleaners, powders, oils, powder foundations, emulsions It may be formulated as a foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a sun cream, flexible lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, pack, spray, face wash, bath or powder.
  • the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. .
  • the formulation is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray additionally chlorofluorohydrocarbon, propane / butane Or propellants such as dimethyl ether.
  • a solvent, solubilizer or emulsion is used as carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 Fatty acid esters of butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose , Aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the developing solvent was 35% ethanol, washed with three times the volume of the filler volume, and then the active fraction was harvested while developing four times the volume of the filler with 80% ethanol.
  • the concentrate was concentrated to a minimum amount for the second open column chromatography to prepare a concentrate.
  • Example 1 The concentrate prepared in 2-1) of Example 1 was subjected to secondary separation and purification using silica gel (silica gel; 55 mm ⁇ 800 mm, 0.40 ⁇ 0.63 ⁇ m) as a filler to obtain an active fraction.
  • silica gel silica gel; 55 mm ⁇ 800 mm, 0.40 ⁇ 0.63 ⁇ m
  • the developing solvent was prepared in chloroform and ethyl acetate (100: 10, 100: 20 or 100: 30) in order to develop the active fraction was collected.
  • the analytical conditions were used by mixing formic acid and acetonitrile solvent in a Shim-pack Prep-ODS (H) Kit 250 mm ⁇ 20 mm column.
  • the detector was PDA (shimadzu SPD-M10Avp) using pure water to separate the septicilide, the solvent was removed with a reduced pressure dryer and then lyophilized to obtain a stipitalid as a powder.
  • Example 1 The stipittalide sample prepared in 2-2) of Example 1 was dissolved in NMR solvent CDCl 3 and placed in a 5 mm tube (Varian Inova-300) for NMR analysis. The results are shown in FIGS. 1 and 2. It was. At this time, tetramethyl silane (TMS) was used as an internal standard reagent.
  • TMS tetramethyl silane
  • the material prepared in 2-2) has a molecular formula of C 9 H 6 O 5 , and has steipitalide (5,8-) having a structure of Formula 1 Dihydroxy-1 H -cyclohepta- [ c ] furan-1,6 (3 H ) -dione).
  • 100 wells of the medium suitable for the target bacteria to be tested were dispensed into 11 wells except the well 2, and 200 ⁇ l of the medium was dispensed into the 12 wells.
  • DMSO dimethyl sulfoxide
  • Spipitalide was dissolved to 200 ⁇ g / ml, and then 100 ⁇ l was dispensed into 1, 2, and 3 wells, and mixed well with the medium.
  • 100 ⁇ l was taken from well 3 and dispensed into well 4 to dilute the stipitalide concentration to 1/2, and in this way to dilute serially to wells 10 well and add to wells 11 and 12. Did not do it.
  • Wells 1, 2 or 12 were used as negative controls and well 11 was used as a positive control.
  • the bacteria to be tested were diluted so that Colony Forming Unit (CFU) was 1,000 / ml, and 100 ⁇ l was dispensed into the wells except for wells 1 and 12 so that the final volume of each well was 200 ⁇ l. It was.
  • CFU Colony Forming Unit
  • Anaerobic bacteria were incubated in a CO 2 incubator, and aerobic bacteria were incubated in a constant temperature incubator for 3 days at 37 ° C, and 20 ⁇ l of almarBlue ® reagent was dispensed into each well to induce color reaction at room temperature for 10 minutes.
  • the growth of the bacteria was classified as the growth of the bacteria when the contents of each well turned red, and the growth was inhibited when the contents of the wells remained blue. Therefore, the concentration starting to turn red was determined as the minimum inhibitory concentration (MIC).
  • the MIC for the bacterium that is an indicator for selecting an antiseptic agent, Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC27853, and Staphylococcus aureus ATCC29213, and other MICs for causing diseases in animals and humans are shown in Table 2 below.
  • Test bacteria MIC ( ⁇ g / ml) Remarks Maniamia Hemoritika ATCC43270MH 16 Pasteurella multocida ATCC43137PM 16 Enterococcus faecalis ATCC29212 32 Salmonella Cholera Suis 32 Salmonella Sui 32 Salmonella typhimurium 64 Streptococcus agalactia 32 Streptococcus uberis 32 Streptococcus Disgalactia 32 Salmonella Entaraitidis 64 Actinobacillus Fleuronimonea ATCC27090AP 64 Histophilus somny ATCC700025HS 64 Staphylococcus pneumoniae ATCC49619 0.25 Escherichia coli ATCC25922 64 Preservative indicators Pseudomonas aeruginosa ATCC27853 One Preservative indicators Staphylococcus aureus ATCC29213 64 Preservative indicators
  • the purified steffitalide from the culture medium of Cordyceps species which is a fungus isolated from insects, is used as an index when selecting preservatives as well as caries, periodontitis and bad breath causing bacteria.
  • Excellent antibacterial activity against fungi, bacteria and animal pathogenic bacteria can be usefully used in cosmetics, food, pharmaceuticals and the like.
  • Melan-a a melanocyte-producing cell (derived from C57BL / 6 mice, sold from Dr. Bennett (Cancer Research Center, London, England)) and from skin cancer (melanoma) cells B16F10 (Korea Cell Line Bank (KCLB)) ) was used.
  • Melan-a cell line contains 10% fetal bovine serum (FBS), 1% penicillin / streptomycin (P / S), 200 nM TPA (12-O-tetradecanoylphorbol-13-acetate) Cultured at 37 ° C., 5% CO 2 incubator using RPMI-1640 medium. B16F10 cell line was maintained at 37 ° C., 5% CO 2 using DMEM medium containing 10% FBS and 1% P / S. Cultured in the incubator.
  • FBS fetal bovine serum
  • P / S penicillin / streptomycin
  • TPA (12-O-tetradecanoylphorbol-13-acetate
  • the cell viability of Melan-a cells was 101.604 ⁇ 0.560% when treated with 100 ⁇ g / ml of arbutin, and 100.118 ⁇ 1.769%, 60 ⁇ g / when treated with 50 ⁇ g / ml of stifitalide. 88.294 ⁇ 8.738% in ml, 86.837 ⁇ 5.251% in 70 ⁇ g / ml, 88.598 ⁇ 4.557% in 80 ⁇ g / ml, 89.962 ⁇ 6.474% at 90 ⁇ g / ml, and 83.581 ⁇ 3.673% at 100 ⁇ g / ml. Therefore, the survival rate was more than 80% in all of the test ranges showed no cytotoxicity.
  • the cell survival rate of B16F10 cells was 100.760 ⁇ 1.245% when treated with 100 ⁇ g / ml of arbutin, and 98.983 ⁇ 5.254% when treated with 50 ⁇ g / ml of steffitalide, and 100.873 ⁇ when treated with 60 ⁇ g / ml. 8.493%, 95.341 ⁇ 1.325% at 70 ⁇ g / ml, 87.584 ⁇ 0.3% at 80 ⁇ g / ml, 87.167 ⁇ 6.707% at 90 ⁇ g / ml, and 86.3 ⁇ 2.332% at 100 ⁇ g / ml. Therefore, the survival rate was more than 80% in all of the test ranges showed no cytotoxicity.
  • Melan-a cell line was incubated at 37 ° C and 5% CO 2 using RPMI-1640 medium containing 10% FBS, 1% P / S and 200 nM TPA, and B16F10 cell line was 10% FBS and 1% DMEM medium containing P / S was incubated in an incubator at 37 °C, 5% CO 2 conditions.
  • the melanin content of 65.2 ⁇ 2.6% was observed when 100 ⁇ g / ml of arbutin, a positive control, was compared with the negative control without treatment in Melan-a cells, and stipitalid was 50 ⁇ g / 72.2 ⁇ 5.5% in ml, 71.8 ⁇ 4.8% at 60 ⁇ g / ml, 69.5 ⁇ 3.8% at 70 ⁇ g / ml, 68.8 ⁇ 5.3% at 80 ⁇ g / ml, 67.6 ⁇ 2.4% at 90 ⁇ g / ml, 100 ⁇ g / The ml showed melanin content of 69.6 ⁇ 2.4%. Therefore, it was confirmed that stipitalid showed melanin synthesis inhibition similar to that of arbutin, a positive control group.
  • the control group when compared to the negative control group without treatment in B16F10 cells, the control group showed a melanin content of 56.0 ⁇ 1.9% at 100 ⁇ g / ml treatment of arbutin, stipitalid 66.0 at 50 ⁇ g / ml ⁇ 4.4%, 64.4 ⁇ 3.9% at 60 ⁇ g / ml, 64.3 ⁇ 5.5% at 70 ⁇ g / ml, 61.0 ⁇ 3.8% at 80 ⁇ g / ml, 55.1 ⁇ 2.7% at 90 ⁇ g / ml, 60.9 at 100 ⁇ g / ml Melanin content of ⁇ 4.0% was shown. Therefore, it was confirmed that stipitalide showed melanin synthesis inhibitory activity similar to that of arbutin, a positive control group.
  • stipitalid isolated from Cordidis spp. which is a fungus isolated from insects, has excellent effects of inhibiting melanin synthesis, and thus may be usefully used for whitening effects in medicines, cosmetics, and the like. Can be.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to: a pharmaceutical composition for preventing or treating oral diseases and a health functional food for improving health, a preservative composition, and a whitening pharmaceutical composition and cosmetic composition, which include (stipitalide, 5,8-dihydroxy-1H-cyclohepta-[c]furan-1,6(3H)-dione) as an effective ingredient. The composition including stipitalide has low toxicity, has good antibacterial activity against various bacteria, can be usefully employed in various oral products and foods, and as preservatives for cosmetics or medicines, and has good inhibitory activity for melanin synthesis so as to be capable of being usefully employed even in whitening-related products.

Description

스티피탈리드를 유효성분으로 포함하는 조성물Composition containing Stifitalide as an active ingredient
본 발명은 하기 화학식 1로 표시되는 곤충 유래 곰팡이균으로부터 추출한 스티피탈리드를 유효성분으로 포함하는 구강 질환 예방 또는 치료용 약학 조성물 및 예방 또는 개선용 건강기능식품, 방부제 조성물 또는, 미백용 약학 조성물 및 화장료 조성물에 대한 것이다. The present invention is a pharmaceutical composition for oral disease prevention or treatment comprising a stipitalid extracted from the insect-derived fungus represented by the formula (1) as an active ingredient and health functional food, preservative composition or whitening pharmaceutical composition for prevention or improvement and It is about a cosmetic composition.
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000001
Figure PCTKR2016012406-appb-I000001
치아 우식증, 치은염, 치주염, 구취 등과 같은 구강 질환은 근본적으로는 스트렙토코커스 뮤탄스(Steptococcus mutans), 포피로모나스 긴기발리스(Porphyromonas gingivalis), 프레보텔라 인터메디아(Prevotella intermedia), 액티노바실러스 액티노마이세템코미탄스(Actinobacillus actinomycetemcomitans), 칸디다 알비칸스(Candida albicans) 등과 같은 병원성 미생물을 포함하는, 칸디다속(Candida spp.)의 구강 병원균으로부터 주로 야기되는 것으로 알려져 있다.Oral diseases such as dental caries, gingivitis, periodontitis, and bad breath are fundamentally caused by Streptococcus mutans, Porphyromonas gingivalis, Prevotella intermedia, and actinobacilli fluid. It is known to be caused mainly by oral pathogens of the Candida spp., Including pathogenic microorganisms such as Actinobacillus actinomycetemcomitans, Candida albicans and the like.
따라서, 종래에는 구강 질환을 치료하기 위하여 상기 구강 병원균들의 생장을 억제하거나 사멸시키는 방안에 대한 연구나 항균 물질에 대한 연구가 주를 이루어 왔다. 그러나 이러한 항균 물질들은 구강 내 유해한 병원균뿐만 아니라, 구강 내 유익한 균까지도 모두 제거하는 것이 대부분이며, 항균 물질의 과도한 사용으로 인하여 항균 물질에 대한 저항성이 증가하거나 유전적 변이가 일어나 내성이 생기는 구강 병원균들이 증가함에 따라 종래와 같은 항균 물질만을 이용하여서는 구강 질환의 예방 또는 치료에 한계가 있다.Therefore, in the related art, a study on the method of inhibiting or killing the growth of the oral pathogens for the treatment of oral diseases has been mainly made. However, most of these antimicrobial agents remove not only harmful pathogens in the oral cavity, but also beneficial bacteria in the oral cavity. Oral pathogens that develop resistance or increase genetic resistance due to excessive use of the antimicrobial agents are used. As it increases, the use of conventional antimicrobial materials alone has limitations in the prevention or treatment of oral diseases.
한편 방부제(Antiseptic: 防腐劑)란 물질의 부패를 막는 약제를 말한다. 동식물성 유기물이 미생물의 작용에 의해 부패하는 것을 막는 것이 방부이고, 보존을 목적으로 방부하기 위해서 첨가하는 약제가 방부제이다. 부패를 일으키는 미생물에는 진균류에 속하는 곰팡이, 효모와 하등미생물인 세균이 있다.On the other hand, antiseptic (防腐劑) is a drug that prevents the corruption of the substance. It is antiseptic to prevent decaying of flora and fauna by the action of microorganisms, and a preservative is a chemical agent added for preservation for the purpose of preservation. Decaying microorganisms include fungi, fungi, yeast and bacteria that are lower organisms.
이러한 방부제는 일반적으로 식품, 화장품 또는 의약품 등의 변질을 막고 그것을 사용하거나 보존하는 동안에 그 순도를 유지시키기 위해서 첨가한다. 따라서 인체에 해가 없어야 한다는 것이 필수조건이고, 또 그 첨가로 인해 품질을 손상시키지 않아야 한다.Such preservatives are generally added to prevent the deterioration of foods, cosmetics or medicines and the like and to maintain their purity while using or preserving them. Therefore, it is essential that there is no harm to the human body, and the addition should not impair the quality.
식품방부제는 식품보존제라고도 하며 음식물이 공기 중에 노출될 때 산화되는 것을 막아주거나 곰팡이나 박테리아 같은 미생물이 음식물을 부패시키는 것을 방지해야 한다. 종래 식품 방부제로는 프로피온산 칼슘, 벤조산 나트륨, 아질산 나트륨과 소르브산 등과 같은 화학 방부제가 사용되어 왔다. 프로피온산은 곰팡이가 생기는 것을 막아주며 빵 치즈 초콜릿 등에 사용한다. 벤조산 나트륨은 오렌지주스나 그레이프 프루트 주스에 첨가하면 미생물의 성장을 막는다. 아질산 나트륨은 육류에서 미생물이 자라는 것을 막아준다. 소르브산과 그 염은 특히 치즈에서 곰팡이나 효모가 자라는 것을 억제한다. 그러나 이러한 화학 방부제는 양이 초과되면 사람이나 가축에 모두 유해하므로 법(약사법 및 식품위생법)으로 그 사용이 규제되고 있다.Food preservatives, also known as food preservatives, should prevent food from being oxidized when exposed to air or prevent microorganisms such as mold and bacteria from corrupting food. As a conventional food preservative, chemical preservatives such as calcium propionate, sodium benzoate, sodium nitrite and sorbic acid have been used. Propionic acid prevents mold and is used in bread, cheese and chocolate. Sodium benzoate, when added to orange juice or grapefruit juice, prevents the growth of microorganisms. Sodium nitrite prevents the growth of microorganisms in meat. Sorbic acid and its salts inhibit the growth of mold and yeast, especially in cheese. However, the use of such chemical preservatives is harmful to both humans and livestock when the amount is exceeded, and their use is regulated by the law (Pharmaceutical Law and Food Sanitation Law).
화장품 방부제는 화장품을 오랫동안 상온에서 보관할 수 있게 만든다. 화장품은 개봉 후 오래 두고 써야 하기 때문에 쉽게 변질되지 않도록 소비자 보호를 위해 방부제(보존)를 넣는다. 화장품에 주로 사용되는 방부제는 메틸 파라벤(Metyl Paraben), 에틸 파라벤(Ethyle Paraben), 프로필 파라벤(Propyl Paraben), 부틸 파라벤(Butyl Paraben), 쿼터늄-15(Quaternium-15), 이미다졸리디닐 우레아(Imidazolidinyl Urea) 등이다. 그러나 화장품은 평생을 두고 인체에 직접 사용하므로 미량의 방부제라 하더라도 인체에 적지 않은 영향을 미칠 수 있다. 실제 피부과 의사들은 피부 트러블 증상 때문에 병원을 찾은 환자의 70%는 그 원인이 화장품 독성(방부제 성분)이라고 말한다. 화장품에 함유된 방부제 성분이 알레르기 반응을 일으키거나 피부에 자극을 줄 수 있다. 최근에는 각종 화장품과 향수에 함유되고 있는 화학물질의 일종인 파라벤(parabens)이 인체 내부에 축적되어 유방암을 일을킬 수 있다는 사실이 밝혀졌다.Cosmetic preservatives allow cosmetics to be stored at room temperature for a long time. Since cosmetics have to be used for a long time after opening, preservatives are added to protect consumers to prevent them from being easily changed. Preservatives commonly used in cosmetics are methyl paraben, ethyl paraben, ethoxy paraben, propyl paraben, butyl paraben, quaternium-15, imidazolidinyl urea (Imidazolidinyl Urea) and the like. However, cosmetics are used directly on the human body for life, so even a small amount of preservatives can have a significant effect on the human body. In fact, dermatologists say that 70% of patients who visit a hospital because of skin problems are caused by cosmetic toxicity (preservatives). Preservatives in cosmetics can cause allergic reactions or irritate the skin. Recently, it has been found that parabens, a kind of chemical contained in various cosmetics and perfumes, can accumulate inside the human body and cause breast cancer.
의약품 방부제로는 벤조산의 나트륨 염 등이 점안제, 수제(水劑), 주사제 등에 첨가되는데, 이러한 화학 방부제는 양이 초과되면 사람에게 치명적 해를 줄 수 있으므로 법(약사법 및 식품위생법)에 의해 그 종류와 사용량이 엄격히 통제되고 있다.As pharmaceutical preservatives, sodium salts of benzoic acid are added to eye drops, homemade medicines, and injections. Such chemical preservatives can cause fatal harm to humans when exceeded, and according to the law (pharmaceutical and food hygiene) And usage are strictly controlled.
상기와 같은 화학방부제들은 인체 안전성에 관한 많은 문제점을 야기하므로, 인체 안전성 측면을 고려하면 자연의 생물로부터 추출하여 얻은 천연 방부제가 사용되는 것이 바람직하다. 지금까지 미생물 오염과 생장을 억제하는 천연 방부제로서 편백나무 추출물인 히노키티올(hinokitiol), 목련 추출물인 메그노놀(megnonol), 자몽종자 추출물인 DF-100 등이 개발되어 있으나 그 규모는 합성 보존제의 17 %에 불과하여 수요를 충족시키지 못하고 있다.Since such chemical preservatives cause many problems regarding human safety, it is preferable to use natural preservatives extracted from natural organisms in consideration of human safety aspects. So far, natural preservatives that suppress microbial contamination and growth have been developed, such as hinokitiol, a cypress extract, megnonole, and DF-100, a grapefruit seed extract. It's only about%, which doesn't meet demand.
사람의 피부색은 표피에 존재하는 색소세포인 멜라닌 세포에서 생성하는 피부멜라닌, 헤모글로빈이나 카로티노이드 등의 색소의 유무 및 피부의 두께와 반사도 등에 영향을 받는다. 이 중 피부색을 결정하는데 가장 중요한 요소인 멜라닌 색소는 인체에 정상적으로 존재하는 아미노산의 일종인 티로신(Tyrosine)이 멜라닌 세포 내에 존재하는 효소인 티로시네이즈(Tyrosinase)에 의해 도파(DOPA)가 되고, 계속되는 일련의 복잡한 산화과정을 통해 최종적으로 흑갈색의 중합체인 멜라닌을 생성하게 된다. 멜라닌 합성은 자외선 노출, 멜라노마(melanoma), 색소과다침착증(hyperpigmentation disease) 등의 요인에 의하여 합성이 촉진된다. 또한, 멜라닌 색소의 생합성은 티로시나제(tyrosinase) 효소를 비롯하여 여러 효소들에 의하여 조절되고 있으며, 그 중 티로시나제는 티로신(tyrosine)을 기질로 하여 L-도파퀴논(L-dopaquinone)으로 전이되는 초기 생합성과정 이후 디하이드록시인돌(dihydroxyindole)의 산화에 작용한다.Human skin color is affected by the presence or absence of pigments such as melanin, hemoglobin or carotenoids produced by melanocytes, which are pigment cells present in the epidermis, and the thickness and reflectivity of the skin. Among these, melanin pigment, which is the most important factor in determining skin color, is typified by tyrosinase, an amino acid that is normally present in the human body, to be dopa (DOPA) by tyrosinase, an enzyme present in melanocytes. Through a series of complex oxidation processes, the result is melanin, a dark brown polymer. Melanin synthesis is promoted by factors such as UV exposure, melanoma, hyperpigmentation disease, and the like. In addition, the biosynthesis of melanin pigment is controlled by various enzymes, including tyrosinase enzymes, among which tyrosinase is an initial biosynthesis process in which tyrosine is transferred to L-dopaquinone as a substrate. It then acts on the oxidation of dihydroxyindole.
그러므로 티로시나제 활성 억제제를 찾는 연구가 미백제의 개발에 있어서 중요한 부분을 차지하고 있으며, 현재 계속 알려지고 있는 티로시나제 저해제로 하이드로퀴논(hydroquinone), 4-하이드록시아니졸(4-hydroxyanisole), 아스코르빈산 (ascorbic acid) 유도체, 코지산(kojic acid), 아젤라인산(azelaic acid), 코르티코스테로이드(corticosteroid), 레티노이드(retinoids), 알부틴(arbutin), 카테킨(catechin) 등이 있으나, 이들의 안전성과 경제성 등의 문제점으로 사용에 있어서 어려움이 있다. Therefore, the search for a tyrosinase activity inhibitor is an important part of the development of the whitening agent, and the known tyrosinase inhibitors are currently known as hydroquinone, 4-hydroxyanisole, and ascorbic acid. acid derivatives, kojic acid, azelaic acid, corticosteroids, corticosteroids, retinoids, arbutin, catechin, etc., but problems such as safety and economics There is a difficulty in using it.
따라서 뛰어난 구강 질환 치료 효과, 방부 효과 또는 피부 미백 효과를 보이는 조성물의 개발이 필요하다.Therefore, there is a need for the development of a composition that exhibits an excellent oral disease treatment effect, antiseptic effect or skin whitening effect.
따라서 본 발명은 구강 질환 치료 효과, 방부 효과 또는 피부 미백 효과를 갖는 화합물을 포함하는 조성물을 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a composition comprising a compound having a therapeutic effect, an antiseptic effect or a skin whitening effect.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of oral diseases comprising the compound of formula 1 as an active ingredient.
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000002
Figure PCTKR2016012406-appb-I000002
또한, 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for preventing or improving oral disease, comprising the compound of Formula 1 as an active ingredient.
또한, 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 방부제 조성물을 제공한다.The present invention also provides a preservative composition comprising the compound of Formula 1 as an active ingredient.
또한, 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
또한, 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
본 발명은 스티피탈리드(stipitalide, 5,8-dihydroxy-1H-cyclohepta-[c]furan-1,6(3H)-dione)를 유효성분으로 함유하는 구강질환 예방 또는 치료용 약학 조성물 및 개선용 건강기능식품, 방부제 조성물, 피부 미백용 약학 조성물 및 화장료 조성물에 대한 것으로, 상기 스티피탈리드는 독성이 낮고 다양한 세균에 대한 항균력이 우수하여 구강관련 다양한 제품과 식품, 화장품 또는 의약품의 방부제로 유용하게 사용될 수 있다. 또한, 멜라닌 합성에 대한 저해활성이 우수하여 미백관련 제품 조성물로도 유용하게 사용될 수 있다. The present invention is a pharmaceutical composition for the prevention or treatment of oral diseases, including steipitalide (5,8-dihydroxy-1 H -cyclohepta- [ c ] furan-1,6 ( 3H ) -dione) as an active ingredient and improvement For health functional food, preservative composition, pharmaceutical composition for skin whitening and cosmetic composition, the stypittalide is low toxicity and excellent antimicrobial activity against various bacteria and useful as a preservative of various products related to oral cavity, food, cosmetics or medicines Can be used. In addition, it has excellent inhibitory activity against melanin synthesis and can be usefully used as a whitening related product composition.
도 1은 스티피탈리드(Stipitalide)의 핵자기공명(nuclear magnetic resonance, NMR) 분석 결과이고,1 is a result of nuclear magnetic resonance (NMR) analysis of Stipitalide (Stipitalide),
도 2는 스티피탈리드의 근적외선 vs 중적외선(Near Infrared vs. Mid Infrared) 분석 결과이고,2 is a result of Near Infrared vs. Mid Infrared analysis of Stipitalide,
도 3 내지 도 5는 스티피탈리드의 구강 질환 관련 균의 생육 억제 활성을 확인한 결과이고,3 to 5 is a result of confirming the growth inhibitory activity of the bacteria associated with oral disease of stipitalid,
도 6 은 멜라닌 생성세포인 Melan-a 세포에 스티피탈리드를 처리한 후 세포 독성을 확인한 결과이고,6 is a result of confirming the cytotoxicity after the treatment of stipitalid to Melan-a cells that are melanin-producing cells,
도 7은 피부암 세포인 B16F10 세포에 스티피탈리드를 처리한 후 세포 독성을 확인한 결과이고,7 is a result of confirming the cytotoxicity after treatment with stipitalid to B16F10 cells, skin cancer cells,
도 8은 Melan-a 세포에 스티피탈리드를 처리한 후 멜라닌 합성 억제 효과를 확인한 결과이고,8 is a result of confirming the melanin synthesis inhibitory effect after the treatment of stipitalid to Melan-a cells,
도 9은 B16F10 세포에 스티피탈리드를 처리한 후 멜라닌 합성 억제 효과를 확인한 결과이다. 9 is a result of confirming the melanin synthesis inhibitory effect after the treatment of stipitalid to B16F10 cells.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 곤충에서 유래된 곰팡이를 에틸 아세테이트(ethyl acetate)로 추출하고 이를 분리, 정제하여 얻은 물질의 활성을 평가하던 중, 이의 우식균을 비롯한 다양한 균에 대한 억제 활성과 멜라닌 생성 억제 활성을 확인하여 본 발명을 완성하였다.The inventors of the present invention, while evaluating the activity of the material obtained by extracting the fungus derived from insects with ethyl acetate (ethyl acetate), isolating and purifying, the inhibitory activity and various melanin production inhibitory activity against various bacteria including caries It was confirmed to complete the present invention.
상기 물질은 하기 화학식 1로 표시되는 스티피탈리드(stipitalide, 5,8-dihydroxy-1H-cyclohepta-[c]furan-1,6(3H)-dione)이며, 홀리카(Holik)와 쿠(Kuhr)의 논문(Miroslav Holik and Ivo Kuhr, J. Chem . Soc.,Chem . Commun . 1973. 65-66)에서 처음으로 화학적 구조가 보고되었지만, 이 물질의 생리활성 효능 효과에 대한 연구는 전무한 상태이다.The material is stipitalide (5,8-dihydroxy-1 H -cyclohepta- [c] furan-1,6 ( 3H ) -dione) represented by the following formula (1), Holika (Holik) and Ku ( Kuhr) 's paper (Miroslav Holik and Ivo Kuhr, J. Chem . Soc., Chem . Commun . 1973. 65-66) for the first time reported a chemical structure, but there is no study on the effect of the biological activity of this substance. to be.
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000003
Figure PCTKR2016012406-appb-I000003
본 발명의 일 실시예에 따르면, 상기 화학식 1로 표시되는 스티피탈리드는 우식균인 스트렙토코쿠스 뮤탄스(Streptococcus mutans) ATCC25175, 스트렙토코쿠스 소르비누스(Streptococcus sorbrinus) ATCC27607와 치주염 원인균인 포르피로모나스 긴기발리스(Porphyromonas gingivalis) ATCC33277, 구취 원인균인 푸소박테리움 누클리아툼(Fusobacterium nucleatum) ATCC23726, 폐렴간균(Klebsiella pneumoniae) ATCC15380의 생육을 효과적으로 억제하였다.According to an embodiment of the present invention, Stypitalide represented by the formula (1) is a streptococcus mutans ( Streptococcus mutans ) is a caries ATCC25175, Streptococcus sorbrinus ATCC27607 and Porphyromonas Gingivalis gingivalis ) ATCC33277, Fusobacterium causes bad breath nucleatum ) ATCC23726 , Klebsiella pneumoniae The growth of ATCC15380 was effectively suppressed.
따라서 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 치료용 약학 조성물을 제공한다.Therefore, the present invention provides a pharmaceutical composition for preventing or treating oral disease, comprising the compound of Formula 1 as an active ingredient.
상기 구강 질환은 치아우식증, 치주염 및 구취로 이루어진 군에서 선택된 어느 하나이나, 이에 제한되는 것은 아니다.The oral disease is any one selected from the group consisting of dental caries, periodontitis and bad breath, but is not limited thereto.
상기 화학식 1의 화합물은 스티피탈리드(stipitalide)로 곤충 유래 곰팡이균인 코르디셉스 종(Cordyceps sp.)의 배양액으로부터 분리 정제한 것을 특징으로 한다.The compound of Formula 1 is characterized in that it was isolated and purified from culture medium of Cordyceps sp.
상기 곤충 유래 곰팡이인 코르디셉스 종은 다른 곰팡이와 마찬가지로 그 성상이 변하기 쉬우며, 이의 돌연변이주, 형질융합체 또는 유전자 재조합체 모두 본 발명의 범위에 포함된다.Cordyceps species, which are insect-derived fungi, are prone to change in appearance, as are other fungi, and all of their mutants, fusions or genetic recombinants are included in the scope of the present invention.
상기 곤충 유래 곰팡이를 이용하여 스티피탈리드를 생산하기 위해서, 상기 균주를 통상 미생물이 이용하는 영양원을 함유하는 배지에서 배양한다. In order to produce stypittalide using the insect-derived fungus, the strain is cultured in a medium containing a nutrient source normally used by microorganisms.
영양원은 탄소원으로서 글루코스(glucose), 프락토스(fructose), 슈크로스(sucrose), 덱스트린(dextrin) 등을 사용하고, 질소원으로서 트립톤(tryptone), 콘스팁리쿼(corn steep liquor, CSL) 등을 사용한다. Nutrients include glucose, fructose, sucrose, dextrin, etc. as carbon sources, and tryptone, corn steep liquor (CSL), etc. as nitrogen sources. use.
배양방법으로는 호기적인 조건에서의 배양법, 특히 액침배양법이 적당하며, 배양은 26 ℃ 내지 30 ℃의 온도범위에서 수행한다.As a culture method, a culture method under aerobic conditions, in particular immersion culture method is suitable, the culture is carried out in a temperature range of 26 ℃ to 30 ℃.
배양이 완료된 후, 배양액을 흡착 크로마토그래피, 에틸 아세테이트 추출, 겔 여과 크로마트그래피 및 고압 액체 크로마토그래피 등의 과정을 통해 목적 화합물을 정제할 수 있다.After the incubation is completed, the target compound may be purified through a process such as adsorption chromatography, ethyl acetate extraction, gel filtration chromatography, and high pressure liquid chromatography.
더불어 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for preventing or improving oral diseases comprising the compound of Formula 1 as an active ingredient.
본 발명의 또 다른 실시예에 따르면, 상기 화학식 1로 표시되는 스티피탈리드는 사람 및 동물에 질병을 유발하는 균으로 알려진 맨하이미아 헤모리티카(Mannheimia haemolytica) ATCC43270MH, 파스튜렐라 멀토시다(Pasteurella multocida) ATCC43137PM, 엔테로코커스 패칼리스(Enterococcus faecalis) ATCC29212, 살모넬라 콜레라수이스(Salmonella choleraesuis), 살모넬라 수이(Salmonella sui), 살모넬라 티피무리움(Salmonella typhimurium), 스트렙토코커스 아갈락티애(Streptococcus agalactiae), 스트렙토코커스 유베리스(Streptococcus uberis), 스트렙토코커스 디스갈락티애(Streptococcus dysgalactiae), 살모넬라 엔타라이티디스(Salmonella enteritidi), 악티노바실루스 플뢰로뉴모니애(Actinobacillus pleuropneumoniae ) ATCC27090, 히스토필루스 솜니(Histophilus somni) ATCC700025 및 스타필로코커스 뉴모니아(Staphylococcus neumoniae) ATCC49619의 생육을 억제하였으며, 특히 방부제 선발 시 지표가 되는 대장균(Escherichia coli) ATCC25922, 녹농균(Pseudomonas aeruginosa) ATCC27853 및 황색포도상구균(Staphylococcus aureus) ATCC29213의 생육도 억제하였다.According to another embodiment of the present invention, stipitalid represented by the formula (1) Mannheimia haemolytica known as bacteria causing diseases in humans and animals ( Mannheimia haemolytica ) ATCC43270MH, Pasteurella multocida ATCC43137PM , Enterococcus faecalis ) ATCC29212, Salmonella choleraesuis , Salmonella sui , Salmonella typhimurium , Streptococcus agalactiae , Streptococcus d'Arcactus , Streptococcus dilacris Streptococcus dysgalactiae), Salmonella yen Tara itty display (Salmonella enteritidi), Tino evil pneumoniae as Bacillus Fleur (Actinobacillus pleuropneumoniae) ATCC27090, Histophilus somni Inhibition of the growth of ATCC700025 and Staphylococcus neumoniae ATCC49619, especially Escherichia coli ATCC25922, Pseudomonas aeruginosa ) ATCC27853 and Staphylococcus aureus ATCC29213 also inhibited the growth.
따라서 본 발명은 하기 화학식 1의 화합물을 유효성분으로 포함하는 방부제 조성물을 제공한다.Therefore, the present invention provides a preservative composition comprising the compound of formula 1 as an active ingredient.
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000004
Figure PCTKR2016012406-appb-I000004
상기 화학식 1의 화합물은 스티피탈리드(stipitalide)로 곤충 유래 곰팡이균인 코르디셉스 종(Cordyceps sp.)의 배양액으로부터 분리 정제한 것이며, 식품, 화장품 또는 의약품에 사용될 수 있다.The compound of Chemical Formula 1 is stetitallide (stipitalide) is purified from the culture medium of the cordyceps sp. (Cordyceps sp.), An insect-derived fungus, can be used in food, cosmetics or pharmaceuticals.
본 발명의 또 다른 실시예에 따르면, 상기 화학식 1로 표시되는 스티피탈리드는 멜라닌 생성세포인 Melan-a 세포 및 피부암(흑색종) 세포인 B16F10 세포에 처리하였을 때 양성대조군인 알부틴(arbutin)과 유사한 수준의 멜라닌 합성 저해능을 보였다.According to another embodiment of the present invention, when stipitalid represented by the formula (1) is treated with melanin-producing Melan-a cells and skin cancer (melanoma) cells B16F10 cells and a positive control group arbutin (arbutin) and Similar levels of melanin synthesis were inhibited.
따라서 본 발명은 하기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 약학 조성물을 제공한다.Therefore, the present invention provides a pharmaceutical composition for skin whitening comprising the compound of formula 1 as an active ingredient.
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000005
Figure PCTKR2016012406-appb-I000005
상기 화학식 1의 화합물은 스티피탈리드(stipitalide)로 곤충 유래 곰팡이균인 코르디셉스 종(Cordyceps sp.)의 배양액으로부터 분리 정제한 것이다.The compound of Chemical Formula 1 is isolated and purified from culture medium of Cordyceps sp., Which is an insect-derived fungus, as stepititalide.
더불어 본 발명은 상기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for skin whitening comprising the compound of Formula 1 as an active ingredient.
본 발명에 따른 약학 조성물은 약학조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 더 포함할 수 있다.The pharmaceutical compositions according to the invention may further comprise suitable carriers, excipients or diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에서 사용가능한 담체, 부형제 또는 희석제로는, 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유 등을 들 수 있다.Carriers, excipients or diluents usable in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
본 발명에 따른 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical compositions according to the present invention may be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물은 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제할 수 있다. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient, for example, starch, calcium carbonate, sucrose ( sucrose, lactose, gelatin and the like can be mixed and prepared.
또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명에 따른 약학조성물의 유효성분인 스티피탈리드의 사용량은 환자의 나이, 성별, 체중, 질환에 따라 달라질 수 있으나, 0.001 내지 50mg/kg으로, 바람직하게는 0.001 내지 5mg/kg을 일일 1회 내지 수회 투여할 수 있다.　The amount of stipitalide which is an active ingredient of the pharmaceutical composition according to the present invention may vary depending on the age, sex, weight, and disease of the patient, but is 0.001 to 50 mg / kg, preferably 0.001 to 5 mg / kg once daily. To multiple administrations.
또한, 본 발명에 따른 스티피탈리드의 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다.　따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.In addition, the dosage of stipitalide according to the present invention may be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
상기 약학조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 기관지내 흡입, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다.The pharmaceutical composition may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrabronchial inhalation, intrauterine dural or intracerebroventricular injection.
더불어 본 발명에 따른 건강기능식품은 분말, 과립, 정제, 캡슐, 시럽 또는 음료의 형태로 제공될 수 있으며, 상기 건강기능식품은 유효성분인 스티피탈리드 이외에 다른 식품 또는 식품 첨가물과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적 예를 들어 예방, 건강 또는 치료적 처치에 따라 적합하게 결정될 수 있다. In addition, the health functional food according to the present invention may be provided in the form of powder, granules, tablets, capsules, syrups or beverages, and the health functional food is used together with other foods or food additives in addition to stipitalide as an active ingredient, and It can be suitably used according to the phosphorus method. The mixed amount of the active ingredient can be suitably determined depending on the purpose of use thereof, for example, prophylactic, health or therapeutic treatment.
상기 건강기능식품의 종류에는 특별한 제한이 없고, 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등을 들 수 있다.There are no particular limitations on the types of dietary supplements, for example, meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea , A drink, an alcoholic beverage, and a vitamin complex.
또한 본 발명에 따른 화장료 조성물은 유효성분인 스티피탈리드 외에 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.In addition, the cosmetic composition according to the present invention may include conventional adjuvants such as stabilizers, solubilizers, vitamins, pigments and flavors, and a carrier, in addition to stipitalide which is an active ingredient.
상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 세정제, 파우더, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 썬 크림, 유연 화장수, 수렴 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 팩, 스프레이, 세안제, 목욕제 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, cleaners, powders, oils, powder foundations, emulsions It may be formulated as a foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a sun cream, flexible lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, pack, spray, face wash, bath or powder.
상기 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. .
상기 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.If the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray additionally chlorofluorohydrocarbon, propane / butane Or propellants such as dimethyl ether.
상기 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해 화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation is a solution or emulsion, a solvent, solubilizer or emulsion is used as carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 Fatty acid esters of butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
상기 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.If the formulation is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose , Aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the present invention. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
<실시예 1> 스티피탈리드(Stipitalide) 생산Example 1 Spititalide Production
1) 코르디셉스 종(Cordyceps sp.)인1) Cordyceps sp. CS429 배양 및 접종 CS429 Culture and Inoculation
먼저 SDA(sabourand dextrose agar)배지에 CS429를 접종하여 항온배양기(27℃, 1주)에서 배양하였다. 그 후 배양된 CS429의 5 조각(8 mm×8 mm)를 취하여 멸균된 액체배지 SDA에 접종하고, 항온진탕배양기(27℃, 180 rpm)에서 4일간 배양하여 배양액을 얻었다.First, inoculated CS429 in SDA (sabourand dextrose agar) medium and incubated in an incubator (27 ℃, 1 week). Thereafter, five pieces (8 mm × 8 mm) of cultured CS429 were taken and inoculated into sterilized liquid medium SDA, and cultured in a constant temperature incubator (27 ° C., 180 rpm) for 4 days to obtain a culture solution.
2) 분리 및 정제2) Separation and Purification
2-1) 충진제로 HP20을 이용한 1차 분리2-1) Primary separation using HP20 as filler
상기 배양액 10 ml을 취한 후, 이를 원심분리기로 분리하여 균사체를 제거하고 상등액만을 취하였다. After taking 10 ml of the culture, it was separated by centrifugation to remove the mycelium and only the supernatant was taken.
이후 충진제로써 HP20(100 mm×1300 mm)을 이용하여 1차 분리를 실시하였다. Thereafter, primary separation was performed using HP20 (100 mm × 1300 mm) as a filler.
전개용매는 35% 에탄올로, 충진제 부피의 3배의 양으로 세척한 후 80% 에탄올로 충진제 부피의 4배로 전개하면서 활성분획을 수확하였다. The developing solvent was 35% ethanol, washed with three times the volume of the filler volume, and then the active fraction was harvested while developing four times the volume of the filler with 80% ethanol.
이후 감압농축기를 사용하여 2차 오픈칼럼 크로마토그래피를 위해 최소한의 양으로 농축하여 농축액을 제조하였다.Thereafter, using a vacuum concentrator, the concentrate was concentrated to a minimum amount for the second open column chromatography to prepare a concentrate.
2-2) 실리카 겔을 이용한 2차 분리2-2) Secondary Separation Using Silica Gel
상기 실시예 1 중 2-1)에서 제조한 농축액을 충진제로써 실리카겔(silica gel; 55 mm×800 mm, 0.40~0.63 ㎛)을 이용하여 2차 분리 및 정제를 실시하여 활성분획을 획득하였다.The concentrate prepared in 2-1) of Example 1 was subjected to secondary separation and purification using silica gel (silica gel; 55 mm × 800 mm, 0.40˜0.63 μm) as a filler to obtain an active fraction.
전개용매는 클로로포름(chloroform)과 에틸 아세테이트(ethyl acetate)를 100:10, 100:20 또는 100:30으로 제조하여 순서대로 전개하여 활성분획을 수집하였다.The developing solvent was prepared in chloroform and ethyl acetate (100: 10, 100: 20 or 100: 30) in order to develop the active fraction was collected.
상기 수집된 분획은 고성능 액체 크로마토그래피(HPLC, shimadzu LC-6AD)를 이용하여 분석하였다. The collected fractions were analyzed using high performance liquid chromatography (HPLC, shimadzu LC-6AD).
분석조건은 Shim-pack Prep-ODS(H) Kit 250 mm×20 mm 컬럼으로 개미산(formic acid)와 아세토니트릴(acetonitrile)용매를 혼합하여 사용하였다. The analytical conditions were used by mixing formic acid and acetonitrile solvent in a Shim-pack Prep-ODS (H) Kit 250 mm × 20 mm column.
유속 0.5 ml/분, 상온, 검출기는 PDA(shimadzu SPD-M10Avp)를 사용하여 스티피탈리드를 순수분리하였고 용매를 감압건조기로 제거한 후 냉동건조하여 분말로서 스티피탈리드를 얻었다.Flow rate 0.5 ml / min, room temperature, the detector was PDA (shimadzu SPD-M10Avp) using pure water to separate the septicilide, the solvent was removed with a reduced pressure dryer and then lyophilized to obtain a stipitalid as a powder.
3) 스티피탈리드의 구조분석3) Structural Analysis of Stiftalide
상기 실시예 1 중 2-2)에서 제조한 스티피탈리드 시료를 NMR용 용매 CDCl3에 녹인 후 5 ㎜ 튜브에 넣어(Varian Inova-300) NMR분석을 하였고, 그 결과를 도 1 및 2에 나타내었다. 이때 내부 표준시약으로 테트라메틸살린(tetra methyl silane, TMS)을 사용하였다.The stipittalide sample prepared in 2-2) of Example 1 was dissolved in NMR solvent CDCl 3 and placed in a 5 mm tube (Varian Inova-300) for NMR analysis. The results are shown in FIGS. 1 and 2. It was. At this time, tetramethyl silane (TMS) was used as an internal standard reagent.
질량분석 및 NMR 스펙트럼 분석 결과를 해석한 결과, 상기 2-2)에서 제조한 물질은 C9H6O5의 분자식을 가지며, 하기 화학식 1의 구조를 가진 스티피탈리드(stipitalide, 5,8-dihydroxy-1H-cyclohepta-[c]furan-1,6(3H)-dione)임을 알 수 있었다.As a result of the analysis of mass spectrometry and NMR spectral analysis, the material prepared in 2-2) has a molecular formula of C 9 H 6 O 5 , and has steipitalide (5,8-) having a structure of Formula 1 Dihydroxy-1 H -cyclohepta- [ c ] furan-1,6 (3 H ) -dione).
[화학식 1][Formula 1]
Figure PCTKR2016012406-appb-I000006
Figure PCTKR2016012406-appb-I000006
<실시예 2> 스티피탈리드의 항균 활성 확인Example 2 Confirmation of Antimicrobial Activity of Stypitalide
상기 실시예 1 중 2-2)에서 제조한 스티피탈리드의 항균 활성을 확인하기 위하여, 하기 표 1과 같이 almarBlue®(A Bio-Rad Company, USA) 방법을 수행하였다.The Example 1 of the styryl prepared in 2-2) in order to determine the antimicrobial activity of the lead Hospital, almarBlue ® as follows in Table 1 (A Bio-Rad Company, USA) method was performed.
1One 22 33 44 55 66 77 88 99 1010 1111 1212
mediummedium -- mediummedium mediummedium mediummedium mediummedium mediummedium mediummedium mediummedium mediummedium mediummedium mediummedium
stipitalidestipitalide stipitalidestipitalide stipitalidestipitalide 1/21/2 1/21/2 1/21/2 1/21/2 1/21/2 1/21/2 1/21/2 -- --
-- cellcell cellcell cellcell cellcell cellcell cellcell cellcell cellcell cellcell cellcell --
2번 웰을 제외한 11개의 웰에 실험하고자 하는 대상균에 적합한 배지 100 μl씩 분주하였고 12번 웰에는 200 μl의 배지를 분주하였다. 디메틸 설폭시화물(Dimethyl sulfoxide, DMSO)에 스티피탈리드를 200 μg/ml가 되게 용해시킨 후 1, 2, 3번 웰에 100 μl씩 각각 분주하여 배지와 잘 혼합하였다. 3번 웰에서 100 μl을 취하여 4번 웰에 분주하여 스티피탈리드 농도가 1/2로 희석되게 하였고 이러한 방법으로 10번 웰까지 연속으로 1/2씩 희석되게 하였으며 11번과 12번 웰에는 첨가하지 않았다. 1번, 2번 또는 12번 웰을 음성 대조군으로 사용하였고 11번 웰은 양성 대조군으로 사용하였다. 더불어 실험하고자 하는 균은 집락형성단위(Colony Forming Unit, CFU)가 1,000/ml이 되게끔 희석하고 1번과 12번 웰을 제외한 나머지 웰에 100 μl씩 분주하여 각 웰의 최종 부피 200 μl가 되게 하였다. 100 wells of the medium suitable for the target bacteria to be tested were dispensed into 11 wells except the well 2, and 200 μl of the medium was dispensed into the 12 wells. In dimethyl sulfoxide (DMSO) Spipitalide was dissolved to 200 μg / ml, and then 100 μl was dispensed into 1, 2, and 3 wells, and mixed well with the medium. 100 μl was taken from well 3 and dispensed into well 4 to dilute the stipitalide concentration to 1/2, and in this way to dilute serially to wells 10 well and add to wells 11 and 12. Did not do it. Wells 1, 2 or 12 were used as negative controls and well 11 was used as a positive control. In addition, the bacteria to be tested were diluted so that Colony Forming Unit (CFU) was 1,000 / ml, and 100 μl was dispensed into the wells except for wells 1 and 12 so that the final volume of each well was 200 μl. It was.
혐기성 균은 CO2 배양기에서 배양하였고 호기성 균은 일반 항온 배양기에서 37℃에서 3일간 충분히 배양한 후 almarBlue® 시약 20 μl를 각각의 웰에 분주하여 10분동안 상온에서 발색반응을 유도하였다. 균의 생육 유무는 각각의 웰의 내용물이 붉은색으로 변하면 균이 생육한 것이고 푸른색으로 유지되면 생육이 억제되는 것으로 구분하였다. 따라서 붉은색으로 변하기 시작하는 농도를 균의 최소억제 농도(Minimum Inhibition Concentration, MIC)로 결정하였다.Anaerobic bacteria were incubated in a CO 2 incubator, and aerobic bacteria were incubated in a constant temperature incubator for 3 days at 37 ° C, and 20 μl of almarBlue ® reagent was dispensed into each well to induce color reaction at room temperature for 10 minutes. The growth of the bacteria was classified as the growth of the bacteria when the contents of each well turned red, and the growth was inhibited when the contents of the wells remained blue. Therefore, the concentration starting to turn red was determined as the minimum inhibitory concentration (MIC).
1) 구강 질환 관련 균의 생육 억제 활성 확인1) Confirmation of growth inhibitory activity of oral disease related bacteria
그 결과 도 3 내지 도 5에 나타난 바와 같이, 주요 우식균인 스트렙토코쿠스 뮤탄스 ATCC25175, 스트렙토코쿠스 소르비누스 ATCC27607에 대한 스티피탈리드의 MIC는 50 μg/ml이었다. 더불어 주요 치주염 유발균인 포르피로모나스 긴기발리스 ATCC33277에 대한 MIC는 25 μg/ml이었고, 주요 구취 유발균인 푸소박테리움 누클리아툼 ATCC23726, 폐렴간균 ATCC15380에 대한 MIC는 각각 50 μg/ml, 6.25 μg/ml인 것으로 확인되었다.As a result, as shown in Figures 3 to 5, the MIC of stipitalid against the main caries bacteria Streptococcus mutans ATCC25175, Streptococcus sorbin ATCC27607 was 50 μg / ml. In addition, the MIC for Porphyromonas gingivalis ATCC33277, the major periodontitis-causing organism, was 25 μg / ml. It was found to be 6.25 μg / ml.
2) 그 외 균의 생육 억제 활성 확인2) Confirmation of growth inhibitory activity of other bacteria
더불어 방부제 선발 시 지표가 되는 세균인 대장균 ATCC25922, 녹농균 ATCC27853, 황색포도상구균 ATCC29213에 대한 MIC와 그 외 동물 및 사람에게 병을 유발하는 세균에 대한 MIC는 하기 표 2에 나타내었다.In addition, the MIC for the bacterium that is an indicator for selecting an antiseptic agent, Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC27853, and Staphylococcus aureus ATCC29213, and other MICs for causing diseases in animals and humans are shown in Table 2 below.
시험대상 균Test bacteria MICMIC (( μgμg /ml)/ ml) 비고Remarks
맨하이미아 헤모리티카 ATCC43270MHManiamia Hemoritika ATCC43270MH 1616
파스튜렐라 멀토시다 ATCC43137PMPasteurella multocida ATCC43137PM 1616
엔테로코커스 패칼리스 ATCC29212Enterococcus faecalis ATCC29212 3232
살모넬라 콜레라수이스Salmonella Cholera Suis 3232
살모넬라 수이Salmonella Sui 3232
살모넬라 티피무리움Salmonella typhimurium 6464
스트렙토코커스 아갈락티애Streptococcus agalactia 3232
스트렙토코커스 유베리스Streptococcus uberis 3232
스트렙토코커스 디스갈락티애Streptococcus Disgalactia 3232
살모넬라 엔타라이티디스Salmonella Entaraitidis 6464
악티노바실루스 플뢰로뉴모니애 ATCC27090APActinobacillus Fleuronimonea ATCC27090AP 6464
히스토필루스 솜니 ATCC700025HSHistophilus somny ATCC700025HS 6464
스타필로코커스 뉴모니아 ATCC49619 Staphylococcus pneumoniae ATCC49619 0.250.25
대장균 ATCC25922 Escherichia coli ATCC25922 6464 방부제 지표Preservative indicators
녹농균 ATCC27853 Pseudomonas aeruginosa ATCC27853 1One 방부제 지표Preservative indicators
황색포도상구균 ATCC29213 Staphylococcus aureus ATCC29213 6464 방부제 지표Preservative indicators
상기 실시예 1 및 실시예 2에서 확인한 바와 같이, 곤충에서부터 분리된 곰팡이균인 코르디셉스 종의 배양액으로부터 분리 정제된 스티피탈리드는 충치, 치주염, 구취 유발균 뿐만 아니라 방부제 선발 시 지표로 사용되고 있는 진균, 세균 및 동물 병원성 세균에 항균력이 뛰어나 화장품, 식품, 의약품 등에 유용하게 이용될 수 있다.As confirmed in Examples 1 and 2 above, the purified steffitalide from the culture medium of Cordyceps species, which is a fungus isolated from insects, is used as an index when selecting preservatives as well as caries, periodontitis and bad breath causing bacteria. Excellent antibacterial activity against fungi, bacteria and animal pathogenic bacteria can be usefully used in cosmetics, food, pharmaceuticals and the like.
<실시예 3> 스티피탈리드의 세포독성 및 미백 효과 확인Example 3 Confirmation of Cytotoxicity and Whitening Effect of Stypitalide
1) 세포독성 시험1) Cytotoxicity Test
스피티탈리드의 세포독성은 최대허용농도(maximum permissible concentration, MPL)를 산출하여 평가하였다.Cytotoxicity of spitalide was assessed by calculating the maximum permissible concentration (MPL).
이를 위하여 멜라닌 생성세포인 Melan-a(C57BL/6 마우스에서 유래, Dr. Bennett(Cancer Research Center, London, England)으로부터 분양)와 피부암(흑색종) 세포인 B16F10(한국세포주은행(KCLB)으로부터 분양)을 사용하였다.To this end, Melan-a, a melanocyte-producing cell (derived from C57BL / 6 mice, sold from Dr. Bennett (Cancer Research Center, London, England)) and from skin cancer (melanoma) cells B16F10 (Korea Cell Line Bank (KCLB)) ) Was used.
Melan-a 세포주는 10% 소태아혈청(fetal bovine serum, FBS)과 1% 페니실린/스트렙토마이신(penicillin/streptomycin, P/S), 200 nM TPA(12-O-tetradecanoylphorbol-13-acetate)가 함유된 RPMI-1640 배지를 사용하여 37℃, 5% CO2조건의 배양기에서 배양하였으며 B16F10 세포주는 10% FBS와 1% P/S가 함유된 DMEM 배지를 사용하여 37℃, 5% CO2조건의 배양기에서 배양하였다.Melan-a cell line contains 10% fetal bovine serum (FBS), 1% penicillin / streptomycin (P / S), 200 nM TPA (12-O-tetradecanoylphorbol-13-acetate) Cultured at 37 ° C., 5% CO 2 incubator using RPMI-1640 medium. B16F10 cell line was maintained at 37 ° C., 5% CO 2 using DMEM medium containing 10% FBS and 1% P / S. Cultured in the incubator.
스티피탈리드가 Melan-a 세포와 B16F10 세포에 미치는 독성을 알아보기 위해 알부틴(arbutin) 100 μg/ml과 스티피탈리드 50, 60, 70, 80, 90 및 100 μg/ml을 각각 처리하고 2일간 배양한 후 540 nm에서 흡광도를 측정하였다.To determine the toxicity of stipitalid to Melan-a cells and B16F10 cells, treatment with 100 μg / ml of arbutin and 50, 60, 70, 80, 90, and 100 μg / ml of spititalide, respectively, and for 2 days After incubation, the absorbance at 540 nm was measured.
그 결과 도 6에서 나타낸 바와 같이, Melan-a 세포의 세포생존율은 알부틴 100 μg/ml 처리시 101.604 ± 0.560%로 나타났으며, 스티피탈리드 50 μg/ml 처리시 100.118 ± 1.769%, 60 μg/ml에서는 88.294 ± 8.738%, 70 μg/ml에서는 86.837 ± 5.251%, 80 μg/ml에서는 88.598 ± 4.557%, 90 μg/ml에서는 89.962 ± 6.474%, 100 μg/ml에서는 83.581 ± 3.673%로 나타났다. 그러므로 시험범위 내에서 모두 80% 이상의 생존율을 보여 세포독성이 나타나지 않았음을 알 수 있었다.As a result, as shown in FIG. 6, the cell viability of Melan-a cells was 101.604 ± 0.560% when treated with 100 μg / ml of arbutin, and 100.118 ± 1.769%, 60 μg / when treated with 50 μg / ml of stifitalide. 88.294 ± 8.738% in ml, 86.837 ± 5.251% in 70 μg / ml, 88.598 ± 4.557% in 80 μg / ml, 89.962 ± 6.474% at 90 μg / ml, and 83.581 ± 3.673% at 100 μg / ml. Therefore, the survival rate was more than 80% in all of the test ranges showed no cytotoxicity.
더불어 도 7에서 나타낸 바와 같이 B16F10 세포의 세포생존률은 알부틴 100 μg/ml 처리시 100.760 ± 1.245%로 나타났으며, 스티피탈리드 50 μg/ml 처리시 98.983 ± 5.254%, 60 μg/ml에서는 100.873 ± 8.493%, 70 μg/ml에서는 95.341 ± 1.325%, 80 μg/ml에서는 87.584 ± 0.3%, 90 μg/ml에서는 87.167 ± 6.707%, 100 μg/ml에서는 86.3 ± 2.332%로 나타났다. 그러므로 시험범위 내에서 모두 80% 이상의 생존율을 보여 세포독성이 나타나지 않았음을 알 수 있었다.In addition, as shown in FIG. 7, the cell survival rate of B16F10 cells was 100.760 ± 1.245% when treated with 100 μg / ml of arbutin, and 98.983 ± 5.254% when treated with 50 μg / ml of steffitalide, and 100.873 ± when treated with 60 μg / ml. 8.493%, 95.341 ± 1.325% at 70 μg / ml, 87.584 ± 0.3% at 80 μg / ml, 87.167 ± 6.707% at 90 μg / ml, and 86.3 ± 2.332% at 100 μg / ml. Therefore, the survival rate was more than 80% in all of the test ranges showed no cytotoxicity.
2) 멜라닌 합성 저해능에 의한 미백효과 확인2) Confirmation of whitening effect by melanin synthesis inhibitory ability
Melan-a 세포주는 10% FBS와 1% P/S, 200 nM TPA가 함유된 RPMI-1640 배지를 사용하여 37℃, 5% CO2조건의 배양기에서 배양하였으며 B16F10 세포주는 10% FBS와 1% P/S가 함유된 DMEM 배지를 사용하여 37℃, 5% CO2조건의 배양기에서 배양하였다.Melan-a cell line was incubated at 37 ° C and 5% CO 2 using RPMI-1640 medium containing 10% FBS, 1% P / S and 200 nM TPA, and B16F10 cell line was 10% FBS and 1% DMEM medium containing P / S was incubated in an incubator at 37 ℃, 5% CO 2 conditions.
Melan-a 세포와 B16F10 세포를 48-웰 플레이트에 적정세포수(2×104 cells/well)만큼 분주하고 37℃, 5% CO2조건의 배양기에서 24시간 배양한 후 알부틴 100 μg/ml과 스티피탈리드를 농도별(50, 60, 70, 80, 90 및 100 μg/ml)로 1차 처치하여 72시간 배양하였다. 배양 후 PBS로 세척하고 다시 동일한 시료의 농도로 2차 처치하여 72시간 배양하고 1N NaOH 용액으로 멜라닌을 용해하여 ELISA 리더기로 490 nm에서 흡광도를 측정하였다. 측정된 흡광도를 기반으로 하기 수학식 1을 통하여 멜라닌 함량을 산출하였다.Melan-a cells and B16F10 cells were dispensed in 48-well plates with the appropriate number of cells (2 × 10 4 cells / well), incubated for 24 hours in an incubator at 37 ° C and 5% CO 2 , followed by 100 μg / ml of arbutin and Stiftalide was firstly treated by concentration (50, 60, 70, 80, 90 and 100 μg / ml) and incubated for 72 hours. After incubation, washed with PBS, and then treated again with the same sample concentration for 72 hours, dissolved melanin in 1N NaOH solution and measured the absorbance at 490 nm with an ELISA reader. The melanin content was calculated through Equation 1 based on the measured absorbance.
[수학식 1][Equation 1]
멜라닌 양(%)=(시료 첨가구의 흡광도/시료 무 첨가구의 흡광도)×100Melanin amount (%) = (absorbance of sample addition / sample non-addition) × 100
그 결과 도 8과 같이, Melan-a 세포에서 시료를 처치하지 않은 음성 대조군과 비교할 때 양성 대조군인 알부틴을 100 μg/ml 처리시 65.2 ± 2.6%의 멜라닌 함량을 보였고, 스티피탈리드는 50 μg/ml에서 72.2 ± 5.5%, 60 μg/ml에서 71.8 ± 4.8%, 70 μg/ml에서 69.5 ± 3.8%, 80 μg/ml에서 68.8 ± 5.3%, 90 μg/ml에서는 67.6 ± 2.4%, 100 μg/ml에서는 69.6 ± 2.4%의 멜라닌 함량을 보였다. 따라서 스티피탈리드는 양성대조군인 알부틴과 유사한 수준의 멜라닌 합성 저해능을 보이는 것을 확인하였다.As a result, as shown in FIG. 8, the melanin content of 65.2 ± 2.6% was observed when 100 μg / ml of arbutin, a positive control, was compared with the negative control without treatment in Melan-a cells, and stipitalid was 50 μg / 72.2 ± 5.5% in ml, 71.8 ± 4.8% at 60 μg / ml, 69.5 ± 3.8% at 70 μg / ml, 68.8 ± 5.3% at 80 μg / ml, 67.6 ± 2.4% at 90 μg / ml, 100 μg / The ml showed melanin content of 69.6 ± 2.4%. Therefore, it was confirmed that stipitalid showed melanin synthesis inhibition similar to that of arbutin, a positive control group.
더불어 도 9와 같이, B16F10 세포에서 시료를 처치하지 않은 음성 대조군과 비교할 때 양성 대조군인 알부틴을 100 μg/ml 처리시 56.0 ± 1.9%의 멜라닌 함량을 보였고, 스티피탈리드는 50 μg/ml에서 66.0 ± 4.4%, 60 μg/ml에서 64.4 ± 3.9%, 70 μg/ml에서 64.3 ± 5.5%, 80 μg/ml에서 61.0 ± 3.8%, 90 μg/ml에서 55.1 ± 2.7%, 100 μg/ml에서는 60.9 ± 4.0%의 멜라닌 함량을 보였다. 따라서 스티피탈리드는 양성대조군인 알부틴과 유사한 수준의 멜라닌 합성 저해능을 보이는 것을 확인하였다..In addition, as shown in Figure 9, when compared to the negative control group without treatment in B16F10 cells, the control group showed a melanin content of 56.0 ± 1.9% at 100 μg / ml treatment of arbutin, stipitalid 66.0 at 50 μg / ml ± 4.4%, 64.4 ± 3.9% at 60 μg / ml, 64.3 ± 5.5% at 70 μg / ml, 61.0 ± 3.8% at 80 μg / ml, 55.1 ± 2.7% at 90 μg / ml, 60.9 at 100 μg / ml Melanin content of ± 4.0% was shown. Therefore, it was confirmed that stipitalide showed melanin synthesis inhibitory activity similar to that of arbutin, a positive control group.
상기 실시예 3에서 살펴본 바와 같이, 곤충에서부터 분리된 곰팡이균인 코르디셉스 종에서 분리 정제된 스티피탈리드는 멜라닌 합성을 억제하는 효과가 뛰어나 의약품, 화장품 등에 미백 효과를 위한 용도로 유용하게 이용될 수 있다.As described in Example 3, stipitalid isolated from Cordidis spp., Which is a fungus isolated from insects, has excellent effects of inhibiting melanin synthesis, and thus may be usefully used for whitening effects in medicines, cosmetics, and the like. Can be.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질직인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is obvious to those skilled in the art that such a specific description is only a preferred embodiment, thereby not limiting the scope of the present invention. something to do. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (10)

  1. 하기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 치료용 약학 조성물.Oral disease prevention or treatment pharmaceutical composition comprising the compound of formula 1 as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2016012406-appb-I000007
    Figure PCTKR2016012406-appb-I000007
  2. 제 1항에 있어서,The method of claim 1,
    상기 화학식 1의 화합물은 곰팡이균인 코르디셉스 종(Cordyceps sp.)의 배양액으로부터 분리 정제한 것을 특징으로 하는 구강 질환 예방 또는 치료용 약학 조성물.The compound of formula 1 is a pharmaceutical composition for the prevention or treatment of oral diseases, characterized in that separated from the culture medium of the fungus Cordyceps sp.
  3. 제 1항에 있어서,The method of claim 1,
    상기 구강 질환은 치아우식증, 치주염 및 구취로 이루어진 군에서 선택된 어느 하나인 것을 특징으로 하는 구강 질환 예방 또는 치료용 약학 조성물.The oral disease is a dental composition for preventing or treating oral disease, characterized in that any one selected from the group consisting of dental caries, periodontitis and bad breath.
  4. 하기 화학식 1의 화합물을 유효성분으로 포함하는 구강 질환 예방 또는 개선용 건강기능식품.Oral disease prevention or improvement health functional food comprising the compound of Formula 1 as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2016012406-appb-I000008
    Figure PCTKR2016012406-appb-I000008
  5. 하기 화학식 1의 화합물을 유효성분으로 포함하는 방부제 조성물.Preservative composition comprising a compound of formula 1 as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2016012406-appb-I000009
    Figure PCTKR2016012406-appb-I000009
  6. 제 5항에 있어서,The method of claim 5,
    상기 화학식 1의 화합물은 곰팡이균인 코르디셉스 종의 배양액으로부터 분리 정제한 것을 특징으로 하는 방부제 조성물.The compound of Formula 1 is a preservative composition, characterized in that separated from the culture medium of the fungus Cordyceps species.
  7. 제 5항에 있어서,The method of claim 5,
    상기 방부제 조성물은 식품, 화장품 또는 의약품에 사용되는 것을 특징으로 하는 방부제 조성물.The preservative composition is a preservative composition, characterized in that used in food, cosmetics or pharmaceuticals.
  8. 하기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 약학 조성물.A pharmaceutical composition for skin whitening comprising the compound of formula 1 as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2016012406-appb-I000010
    Figure PCTKR2016012406-appb-I000010
  9. 제 8항에 있어서,The method of claim 8,
    상기 화학식 1의 화합물은 곰팡이균인 코르디셉스 종의 배양액으로부터 분리 정제한 것을 특징으로 하는 피부 미백용 약학 조성물.The compound of Formula 1 is a skin whitening pharmaceutical composition, characterized in that separated from the culture medium of the fungus Cordyceps species.
  10. 하기 화학식 1의 화합물을 유효성분으로 포함하는 피부 미백용 화장료 조성물.A cosmetic composition for skin whitening comprising the compound of formula 1 as an active ingredient.
    [화학식 1][Formula 1]
    Figure PCTKR2016012406-appb-I000011
    Figure PCTKR2016012406-appb-I000011
PCT/KR2016/012406 2015-11-03 2016-10-31 Composition including stipitalide as active ingredient WO2017078353A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0153916 2015-11-03
KR1020150153916A KR101711603B1 (en) 2015-11-03 2015-11-03 Composition comprising stipitalide as active ingredients

Publications (1)

Publication Number Publication Date
WO2017078353A1 true WO2017078353A1 (en) 2017-05-11

Family

ID=58410635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/012406 WO2017078353A1 (en) 2015-11-03 2016-10-31 Composition including stipitalide as active ingredient

Country Status (2)

Country Link
KR (1) KR101711603B1 (en)
WO (1) WO2017078353A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471628B (en) * 2020-06-04 2022-02-15 内蒙古农业大学 New streptococcus and application of preparation thereof in inhibiting oral pathogenic bacteria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110023892A (en) * 2008-06-25 2011-03-08 바스프 에스이 Use of benzotropolone derivatives as uv absorbers and antioxidants and their use in sunscreens and/or cosmetic compositions
WO2012013967A2 (en) * 2010-07-28 2012-02-02 Syntopix Group Plc New uses
KR20120102628A (en) * 2009-10-06 2012-09-18 바스프 에스이 Stabilization of household, body-care and food products by using benzotropolone containing plant extracts and/or related benzotropolone derivatives
WO2012172318A1 (en) * 2011-06-17 2012-12-20 Evocutis Plc Formulations containing tropolonoids, copper salt and a solvent system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495272B1 (en) 2011-11-11 2015-02-24 바이오스펙트럼 주식회사 Compositions containing 3-(dodecanoyloxy)-2-(isobutyryloxy)-4-methylpentanoic acid As Active Ingredients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110023892A (en) * 2008-06-25 2011-03-08 바스프 에스이 Use of benzotropolone derivatives as uv absorbers and antioxidants and their use in sunscreens and/or cosmetic compositions
KR20120102628A (en) * 2009-10-06 2012-09-18 바스프 에스이 Stabilization of household, body-care and food products by using benzotropolone containing plant extracts and/or related benzotropolone derivatives
WO2012013967A2 (en) * 2010-07-28 2012-02-02 Syntopix Group Plc New uses
WO2012172318A1 (en) * 2011-06-17 2012-12-20 Evocutis Plc Formulations containing tropolonoids, copper salt and a solvent system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOLK, M. ET AL.: "Determination of the Structure of Stipitalide, a New Tropolone from Penicillium Stipilatum Thorn", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, vol. 3, 1973, pages 65 - 66 *

Also Published As

Publication number Publication date
KR101711603B1 (en) 2017-03-03

Similar Documents

Publication Publication Date Title
WO2014193014A1 (en) Nano-sized kimchi lactic acid bacteria
WO2019103329A1 (en) Antioxidant composition comprising fermented mealworm extract as active ingredient
US20070161579A1 (en) Flavanone compound and uses thereof
WO2014084572A1 (en) Catechin bioavailability enhancer comprising cyclodextrin
WO2019225785A1 (en) Antimicrobial and antifungal composition comprising eugenol and gallic acid as active ingredients
WO2022080839A1 (en) Antioxidant, anti-inflammatory and whitening composition comprising skin-derived lactic acid bacteria
WO2019225786A1 (en) Antibacterial and antifungal composition comprising extract from clove, hibiscus, and coconut as effective ingredient
WO2021080129A1 (en) Composition for strengthening skin barrier and alleviating atopic dermatitis, having hydrangenol or phyllodulcin as active ingredient
JPH06192114A (en) Medicine comprising extract of hydrangeae dulcis folium as active ingredient and food and cosmetic containing the same blended therein
WO2017078353A1 (en) Composition including stipitalide as active ingredient
WO2017023099A1 (en) Composition for increasing intestinal lactic acid bacteria and method for producing lactic acid bacteria using same
WO2015034247A1 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis
WO2018230906A1 (en) Whitening composition containing novel quercetin-based compound
WO2019059572A2 (en) Novel antimicrobial peptide derived from skate skin and use thereof
KR101880000B1 (en) Composition for Preventing or Treating Oral Disease Comprising Stipitalide as Active Ingredients
WO2021242056A1 (en) Bifidobacterium sp. strain and extracellular vesicle derived therefrom, and anti-inflammatory and anti-bacterial uses thereof
KR101791407B1 (en) Composition for Skin Whitening Comprising Stipitalide as Active Ingredients
WO2020111540A1 (en) Pharmaceutical composition for preventing or treating aging or aging-related diseases comprising anthocyanin-polysaccharide complex as active ingredient
WO2021080298A1 (en) Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
KR102297957B1 (en) A composition for improving, preventing and treating of acne and atopic dermatitis comprising black garlic extract
WO2019172666A1 (en) Novel antimicrobial peptide derived from ll37 peptide and use thereof
WO2018230909A1 (en) Anti-inflammatory composition including novel kaempferol-based compound derived from post-fermented tea
EP2349297B1 (en) Composition comprising aceriphyllum rossii extract and active compounds isolated from them for use in the treatment of bacterial infections
WO2018155933A1 (en) 6,7-dimethoxy-2,2-dimethyl-2h-chromene for increasing expression of aquaporin-3 and use thereof
WO2013025074A2 (en) Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16862369

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16862369

Country of ref document: EP

Kind code of ref document: A1